Table 1.
Patient characteristics
| Demographic data | Values |
|---|---|
| Age, yr | |
| Mean ± SE (range) | 52.7 ± 1.2 (28–76) |
| BMI, kg/m2 | |
| Mean ± SE (range) | 27.8 ± .64 (18.6–51.4) |
| Diabetes (n, %) | 7 (6.7) |
| Prescribed CIPN treatment, n (%) a | 9 (8.6) |
| Breast cancer stage, n (%) | |
| I | 6 (5.7) |
| II | 47 (44.8) |
| III | 37 (35.2) |
| IV | 7 (6.7) |
| Unknown | 8 (7.6) |
| Receptor status, n (%) | |
| ER positive | 71 (67.6) |
| PR positive | 58 (55.2) |
| HER2 positive | 27 (25.7) |
| Unknown | 3 (2.85) |
| Time since taxane treatment, mo | |
| Mean ± SE (range) | 3.57 ± .16 (2–8) |
| Cumulative paclitaxel dose, mean ± SE (range), mg/m2 | |
| Prospective cohort (n = 83) | 861.8 ± 15.9 (474–960) |
| Whole cohort (n = 105) | 848.9 ± 14.8 (400–960) |
| No dose modification (n = 53) | 960.0 ± 0 |
| Any dose modification (n = 52) | 736.0 ± 20.0 (400–940) |
| Early cessation (6–9 cycles) (n = 19) | 582.1 ± 29.9 (400–720) |
| Late cessation (10–11 cycles) (n = 25) | 817.8 ± 12.6 (660–880) |
| No treatment discontinuation (n = 61) | 944.7 ± 5.6 (760–960) |
| Reason for dose modification, n (%) | |
| Neuropathy | 38 (36.2) |
| Other b | 14 (13.3) |
a
Patient taking medication to treat CIPN at time of assessment including pregabalin and gabapentin.
b
Neutropenia or thrombocytopenia (n = 3), fluid retention (n = 2), patient travel (n = 2), abnormal liver function (n = 1), arthralgias (n = 1), cardiovascular concerns (n = 1), diarrhea (n = 1), fever (n = 1) and unspecified (n = 2).
Abbreviations: BMI, body mass index; CIPN, chemotherapy‐induced peripheral neuropathy; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor.